Linked Life Data

18704558

Source:http://linkedlifedata.com/resource/pubmed/id/18704558

Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
4
pubmed:dateCreated
2009-7-24
pubmed:abstractText
The Blue Pacific study assessed the effect of injectable poly-L-lactic acid (PLLA) (Sculptra; Dermik Laboratories, a business of Sanofi-Aventis U.S. LLC, Bridgewater, NJ, USA) for the treatment of human immunodeficiency virus (HIV)-associated facial lipoatrophy. This case report describes a patient treated originally with injectable PLLA in the Blue Pacific study, then retreated with injectable PLLA 12 months after completion of his initial treatment sessions. Retreatment was well tolerated and resulted in a correction of facial lipoatrophy for a duration of 2 years 7 months.
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:month
Jul
pubmed:issn
1432-5241
pubmed:author
pubmed:issnType
Electronic
pubmed:volume
33
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
654-6
pubmed:meshHeading
pubmed:year
2009
pubmed:articleTitle
Duration of correction for human immunodeficiency virus-associated lipoatrophy after retreatment with injectable poly-L-lactic acid.
pubmed:affiliation
Blue Pacific Aesthetic Medical Group, Inc., 2301 Rosecrans Avenue, Suite 1135, El Segundo, CA 90245, USA. DRMEST@aol.com
pubmed:publicationType
Journal Article, Case Reports